Adnexal torsion is the rotation of the ovary around its vascular axis resulting, in the absence of treatment, ischemia that can lead to peritonitis by necrosis or impaired fertility. It is a gynecological emergency affecting 3% of women of childbearing age, including from adolescence, and requires surgical treatment as soon as possible, classically within 6 hours.
The symptomatology of adnexal torsion is dominated by pelvic pain of sudden onset and variable intensity, an aspecific sign that does not allow a diagnosis of certainty. There are no biological markers and, in the context of the emergency, the only imaging examination available is pelvic ultrasound associated with a Doppler flow analysis but with a low and variable diagnostic performance depending on the studies (sensitivity variable from 46 to 73%).
There are currently no tests that can provide a diagnosis of certainty. Only surgical exploration, carried out at the discretion of the practitioner on the basis of a bundle of arguments, can confirm or refute the diagnosis. However, this management strategy leads to the realization of emergency surgical interventions wrongly since 3 out of 10 women will finally not have an adnexal torsion (PMSI data from participating centers: 30 to 45% false positives).
Contrast ultrasound is a technique that uses a strict intravascular product to assess the vascularization of the ovary and offers a high diagnostic performance in the context of adnexal torsion. Indeed, a retrospective study, published in 2021, reports a sensitivity of 94% and a specificity of 100%. The preliminary results of our pilot study (AGATA APJC 2019, Dr Bertholdt, NCT04522219) also go in this direction with a sensitivity of 100%, a specificity of 86% and a negative predictive value of 100% (data being published).
The COVARIAN project, second stage of the AGATA project, aims to demonstrate that the addition of a contrast evaluation to standard ultrasound in the diagnostic strategy in case of suspicion of adnexal torsion improves the health of women by reducing the rate of wrongly surgery, that is, without proven torsion.
COVARIAN will be the first prospective multicenter randomized study evaluating the direct benefit for women of using ultrasound contrast evaluation in the management strategy in case of suspicion of adnexal torsion.

Start Date20 Mar 2025

Sponsor / Collaborator

Centre Hospitalier Regional de Nancy

NCT06693752

/ RecruitingPhase 2

Pilot Study of Improved Diagnosis and Monitoring of Hydrocephalus in Neonates and Infants Using Contrast-Enhanced Ultrasound

Hydrocephalus affects up to 2 out of every 500 births and results in long-term disability in up to 78% of those affected. The standard treatment of hydrocephalus is cerebrospinal fluid (CSF) diversion via placement of an invasive ventricular shunt to relieve elevated intracranial pressure (ICP). The clinical decision for CSF diversion is based on the ventricular size and clinical symptoms which are not robust indicators of brain health in neonatal hydrocephalus. The purpose of this study is to assess the safety and feasibility of performing brain contrast-enhanced ultrasound (CEUS) in neonates and infants with diagnosed and/or suspected hydrocephalus.

Start Date15 Feb 2025

Sponsor / Collaborator

The Children's Hospital of Philadelphia

NCT06600880

/ Not yet recruitingPhase 1IIT

Neuronavigation-guided Focused Ultrasound-induced Blood-brain Barrier Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau

The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a single-element transducer with neuronavigation guidance. Preliminary results from our phase 1a study demonstrate that our neuronavigation-guided FUS system was capable of safely and transiently open the BBB in participants with AD. The information collected in this new study may be used to design future clinical trials to ultimately provide a viable alternative for treatment of AD in a safe and noninvasive manner.
Our secondary objective includes the assessment of the therapeutic efficacy of FUS-BBBO in reducing amyloid beta and neurofibrillary tangles, the main hallmark pathologies of AD, using PET tracers. Based on our preclinical studies in AD transgenic mouse models, FUS-BBBO alone was able to reduce both the amyloid beta and tau protein load, resulting in improvements in behavioral tasks assessing memory. Therefore, in this new study, the effect of FUS-BBBO on the amyloid beta and tau protein load in patients with AD will be assessed through the use of PET tracers.

Start Date01 Oct 2024

Sponsor / Collaborator

The Trustees of Columbia University in The City of New York

100 Clinical Results associated with Sulfur Hexafluoride Lipid-Type A Microspheres

100 Translational Medicine associated with Sulfur Hexafluoride Lipid-Type A Microspheres

100 Patents (Medical) associated with Sulfur Hexafluoride Lipid-Type A Microspheres

21,835

Literatures (Medical) associated with Sulfur Hexafluoride Lipid-Type A Microspheres

01 Jul 2025·Separation and Purification Technology

In-situ activated carbon adsorbents with tailored pore structures for efficient SF6 capture and high-purity recovery

Author: Li, Yulin ; Sui, Zhuyin ; Xu, Xiufeng ; Fu, Wenxu ; Wang, Jian ; Shi, Ying

Developing adsorbents with optimized pore size distributions that maximize SF₆ adsorption capacity while minimizing N₂ uptake remains a key research focus for efficient separation and recovery of SF₆ from N₂.This study aims to develop carbon-based adsorbents with optimized pore structures to enhance the selective adsorption of SF₆.Using in-situ activation method, KHP-T carbon materials were synthesized from potassium hydrogen phthalate (KHP) at various pyrolysis temperatures (T).The pore size distribution, particularly in the ranges of 0.36-0.52 nm and 0.52-0.80 nm, was systematically tuned and characterized.The optimized material, KHP-800, exhibited a significant proportion of pores in the 0.52-0.80 nm range for SF₆ accommodation while minimizing N₂ adsorption.Thus, it demonstrated the highest SF₆ adsorption capacity (2.41 mmol·g^-1 at 10 kPa) with lower adsorption energy of 25.0 kJ·mol^-1, surpassing all carbon adsorbents reported in literature.Furthermore, dynamic breakthrough experiments further confirmed its efficient and stable separation performance, and the desorption of 1.2 mmol·g^-1 of SF₆ at 99.9% purity under 298 K set a new benchmark for high-purity gas recovery.These findings provide valuable insights into the design of carbon materials for selective SF₆ adsorption and highlight the potential of in-situ activation methods for tuning pore structures to enhance gas separation efficiency.

01 Jul 2025·Separation and Purification Technology

Silica-polysiloxane nanocomposite membrane via 2-step atmospheric-pressure PECVD for precise molecular-sieving H2 separation

Author: Nagasawa, Hiroki ; Moriyama, Norihiro ; Kawasaki, Mitsugu ; Kanezashi, Masakoto ; Tsuru, Toshinori

Silica-based membranes exhibit excellent mol. sieving properties and robustness to achieve efficient mol. separationIn recent years, polymer-supported silica-based membranes have been proposed as a cost-effective alternative to ceramic-supported membranes due to their lower cost and ease of scalability.In this study, we developed a two-step atm.-pressure plasma-enhanced chem. vapor deposition (AP-PECVD) process for fabricating polymer-supported silica-based membranes with enhanced mol. sieving properties.Our approach involves sequentially depositing a polysiloxane-like layer followed by forming a silica-like layer, allowing precise control over the siloxane network pore sizes.On the other hand, by stacking these layers, we achieved a significant improvement in hydrogen selectivity, with H₂/N₂ and H₂/CH₄ permeance ratios of 53.1 and 54.4, resp., with H₂ permeance of 6.23 x 10^-8 mol/(m² s Pa).Characterization through FTIR and SEM anal. revealed that the first layer not only effectively covered the porous polymeric support but also underwent oxidation, facilitating uniform deposition of the second silica layer to improve selectivity.This scalable process, conducted under ambient conditions, atm. pressure and low temperature, offers a cost-effective and versatile platform for fabricating highly selective polymer-supported silica membranes for mol. separation

01 Jun 2025·MethodsX

A new airtight sampling method for sulfur hexafluoride (SF6) in groundwater

Article

Author: Leslie, Deborah ; Sunderland, Raka ; Schoefernacker, Scott ; Larsen, Dan

In the past 20 years, sulfur hexafluoride (SF₆) has been considered a highly reliable tracer for assessing modern water (< 65 yrs old) in groundwater. However, modern-air contamination may introduce complications in interpreting data obtained using current sampling methods. A new airtight methodology isolates the sample from modern ambient air; thus, returning more reproducible and reliable results when compared to two traditional (air-sensitive and non-airtight) methods. The new airtight method returned results within 0.03-0.05 fmol/L SF₆ of expected SF₆ concentration for pre-modern waters (0.02-0.09±0.01 fmol/L). In contrast, the air-sensitive and non-airtight traditional methods returned results within 0.00-0.90 fmol/L and 0.02-1.21 fmol/L of the expected value, respectively. It is suspected that transformers in proximity to wells leak SF₆ which subsequently partitions into the samples obtained using traditional air-sensitive and non-airtight methods, thus creating erratic SF₆ results.•Comparative analyses of a new airtight method with traditional methods were performed and returned lower SF₆ concentrations with the new 2022 airtight method.•The new airtight method shows reproducible low-level detection of SF₆ concentrations and may reduce sampling error in production wells in urban areas that are co-located with transformers which are SF₆-emitting sources.

News (Medical) associated with Sulfur Hexafluoride Lipid-Type A Microspheres

27 Feb 2023

·www.sciencedaily.com

New superacid converts harmful compounds into sustainable chemicals

Researchers have succeeded in producing very special catalysts, known as 'Lewis superacids', which can be used to break strong chemical bonds and speed up reactions. The production of these substances has, until now, proven extremely difficult. The chemists' discovery enables non-biodegradable fluorinated hydrocarbons, similar to Teflon, and possibly even climate-damaging greenhouse gases, such as sulphur hexafluoride, to be converted back into sustainable chemicals. Researchers at Paderborn University have succeeded in producing very special catalysts, known as "Lewis superacids," which can be used to break strong chemical bonds and speed up reactions. The production of these substances has, until now, proven extremely difficult. The chemists' discovery enables non-biodegradable fluorinated hydrocarbons, similar to Teflon, and possibly even climate-damaging greenhouse gases, such as sulphur hexafluoride, to be converted back into sustainable chemicals. The researchers have now published their results in the journal Angewandte Chemie (Applied Chemistry). "Lewis acids" are compounds that add electron pairs. Because of this ability, they are often used to speed up chemical reactions. Lewis superacids are stronger than antimony pentafluoride -- the strongest Lewis acid -- and can break even the toughest bonds. Professor Jan Paradies from the Department of Chemistry at Paderborn University explains: "For strong bonds, you need highly reactive reagents, i.e. substances that are extremely reactive." The new catalyst can split, for example, carbon-fluorine or sulphur-fluorine bonds, which are particularly robust. "Intrinsically, these Lewis superacids are incredibly reactive, which makes them difficult to produce and use. Using a trick, we managed to produce such molecules and use them in catalytic reactions. This makes it possible to, for example, activate and further convert virtually inert, i.e. less reactive, carbon-fluorine or sulphur-fluorine bonds," says Paradies. The researchers in the Department of Chemistry have joined forces in the Center for Sustainable Systems Design (CSSD), which bundles interdisciplinary basic research in the field of sustainability at Paderborn University. The complementary scientific interests of the groups involved form the nucleus for new approaches in the development of sustainable systems. The centre wants to leverage this capacity to contribute to the sustainable use of resources. This and related topics are also covered in Paderborn within the framework of its "Sustainable Chemistry" master's programme.

21 Feb 2023

·www.biospace.com

Enhanced Ultrasound Superior to MRI for Diagnosing Certain Liver and Kidney Tumors, According to New Studies

CHICAGO--(BUSINESS WIRE)-- Contrast-enhanced ultrasound (CEUS) is more accurate and reliable than MRI for examining certain liver and kidney nodules, according to two new studies published in the Journal of Ultrasound in Medicine (JUM) and highlighted by the International Contrast Ultrasound Society (ICUS). “We found that CEUS is a better and less expensive first-step evaluation for newly-discovered liver nodules,” said Dr. Stephanie Wilson, principal investigator of the liver CEUS study, which followed 196 patients at the University of Calgary for two years. Dr. Wilson is a clinical professor of radiology and gastroenterology at the University of Calgary and Co-President of ICUS. “CEUS found malignant or pre-malignant diagnoses that would likely have been missed or delayed if we had not used CEUS in these patients,” according to Dr. Wilson. “In addition, CEUS quickly and reliably identified benign lesions and pseudo-lesions, sparing these patients the costs and risks associated with unnecessary downstream testing and procedures,” she added. This study shows that CEUS scans are at least equivalent if not superior to MRI for evaluating these liver lesions, and CEUS should be the first investigation for nodules found on surveillance for liver cancer, according to Dr. Wilson. She called upon the American Association for the Study of Liver Diseases (AASLD) to include CEUS in its liver imaging guidelines, along with MRI and CT. Meanwhile, an Ohio team reviewed clinical data over a 10 year period to assess the accuracy of CEUS diagnoses of benign kidney nodules in 341 patients. Their blinded analysis found that none of the CEUS diagnoses changed during that period. “Our data confirm that when CEUS determines a kidney mass is benign, the mass is benign and no further follow up is needed -- sparing the patient from unnecessary downstream tests, anxiety and costs,” according to Dr. Richard G. Barr, the lead author of the kidney CEUS study. Dr. Barr is a professor of radiology at the Northeast Ohio Medical University and treasurer of ICUS. CEUS is a non-invasive imaging tool that is safely and routinely used worldwide to help identify and characterize cancers, diagnose heart and vascular disease, monitor chronic gastro-intestinal diseases and monitor therapy. Ultrasound contrast agents are administered intravenously to enhance the images produced by ultrasound scans, allowing for visualization of abnormal microvascular blood flow patterns in real time. “It is important to remember that ultrasound contrast agents do not contain iodinated dye and do not harm the kidneys, making CEUS the examination of choice for patients with renal insufficiency,” according to Dr. Barr. “In addition, CEUS allows for improved visualization of enhancement patterns in real time, the thin slice thickness of CEUS allows for evaluation of small nodules, multiplanar imaging allows for improved visualization and confirmation of enhancement, and multiple doses may be used during the same examination to provide an opportunity to image the lesion thoroughly,” Dr. Barr said. Since kidney masses are often found on imaging for other indications, CEUS offers an essential imaging option because it is safe, accurate, low-cost, radiation-free and can help these patients avoid additional unnecessary tests and surgery, he added. “Further, due to radiation exposure associated with CT, we believe CT should not be used as the first line imaging modality for assessing cystic lesions that are most probably benign in character,” Dr. Barr said, citing the FDA’s recent white paper addressing unnecessary radiation exposure from medical imaging. Many urologists are now also finding that CEUS is essential for diagnosing indeterminate kidney masses. “If CEUS shows concern for malignancy of renal masses, we have complete confidence in proceeding with treatment; and if CEUS confirms a lesion to be benign our Urology group feels equally assured that it is safe to follow such lesions over time and to forego treatment,” said Dr. Daniel Ricchiuti, a urologist in Boardman, Ohio. The Canadian liver study represents the first prospective comparison of CEUS and contrast-enhanced MRI for assessment of newly-discovered liver nodules, according to Dr. Wilson. She said her study showed that CEUS offers superior sensitivity when compared to MRI (81% vs 64%) for the diagnosis of malignancy, without compromising specificity (92% vs. 93%). In addition, CEUS was more likely than MRI to reproduce and characterize the nodule found on screening (97% vs. 78.5%). Nonetheless, MRI remains an essential tool for managing patients with malignant tumors, particularly for staging these tumors prior to treatment, according to Dr. Wilson. Four ultrasound contrast agents are available in various countries around the world: Sonovue (Lumason in the USA), manufactured and sold by Bracco; Definity (Luminity in Europe), manufactured and sold by Lantheus; and Optison and Sonazoid, manufactured and sold by GE Healthcare. ABOUT ICUS: The International Contrast Ultrasound Society (ICUS) is a non-profit medical society dedicated to advancing the medically appropriate use of contrast enhanced ultrasound (CEUS) to improve patient care and outcomes. ICUS offers free membership, CME-accredited webinars, newsletters, a comprehensive CEUS website and new mobile app, “ICUS Connect.” To join ICUS and learn more about CEUS, please visit .

Radiation Therapy

24 Nov 2022

·www.prnewswire.com

A "Rheumatoid Arthritis" clinical study conducted by China Medical University Hospital (CMUH) was published on the American Association of Immunologist.

The study also won 2022 Future Technology Award in Taiwan. TAICHUNG,Taiwan, Nov. 24, 2022 /PRNewswire/ -- A clinical study to explore the influence of BR1 on rheumatoid arthritis conducted by Professor Gregory J. Tsai from China Medical University Hospital (CMUH) in Taiwan was published at a meeting of the American Association of Immunologist (AAI), a top medical society in the US. Continue Reading Figure: In 2022, Professor Gregory J. Tsay published a clinical study to explore the influence of BR1 on rheumatoid arthritis at a meeting of the American Association of Immunologists (AAI), a top medical society in US. In the study, Dr. Gregory J. Tsay explained that rheumatoid arthritis belongs to a kind of autoimmune disease with chronic inflammation and deteriorating issues and impacts 0.5-1% of the population, Most patients are female and around 40 years old. The prevalence of arthritis in the US and China exceeds 50 million and 100 million people, respectively. The number of patients continue to grow every year. Patients usually feel joint pain, swelling, and stiffness. In particular, Dr. Gregory J. Tsay stated that many studies have indicated that rheumatoid arthritis is closely correlated with periodontal disease. The major pathogen of periodontal disease is Porphyromonas gingivalis, which generates many toxic factors, including gingipains, with many domains like RgpA (arginine gingipain) and Kpg (lysine gingipain). Therefore, the R&D team led by Dr. Gregory J. Tsay planned to determine a section of peptides for rheumatoid arthritis diagnosis in the pathogen of periodontal disease. This innovative serological target-based test has been developed as a diagnostic kit with ELISA (Anti-BR1 IgG ELISA Kit) for clinical diagnosis. The diagnosis of rheumatoid arthritis primarily relies on two serological tests of "rheumatoid factor (RF)" and "antibody against citrullinated protein antigens (ACPA)," but no less than 30% of rheumatoid arthritis patients have negative RF or ACPA tests. Since no single test can confirm the diagnosis of rheumatoid arthritis, physicians need to combine patients' signs and symptoms, joint examination, x-rays, blood tests, etc. to rule out the diagnosis. However, physicians may be unable to prescribe the reimbursed treatments for the patients if their diagnostic test scores do not meet the criteria. Therefore, a more innovative biological labeling marker is required to improve the sensitivity of the tests and assess the treatment responses to relieve disease conditions and move toward additional treatments. In a recent case at China Medical University Hospital, Ms. Huang, a 37-year-old woman, began frequently experiencing joint redness, swelling, and pain since she was 18 years old. When she woke up in the morning, she would feel body stiffness, swelling in both knees swelling, and difficulty standing up; even her daily walking would be influenced. Because her father had a history of gout, she went to a hospital to seek help at 21 years old and was diagnosed with gout by the doctor. Afterward, she started to control her diet and undergo treatment with medication. However, she did not feel any better. By the time she was 23 years old, she visited the OPD of a well-known top physician of the Rheumatology and Immunology specialty, Professor Gregory J. Tsay. (Dr. Gregory J. Tsay) checked the patient and made an initial diagnosis ruled as rheumatoid arthritis, but both her rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) tests showed negative and were unable to confirm the diagnosis. Therefore, Dr. Gregory J. Tsay's team began studying a new test for rheumatoid arthritis, which is abbreviated as the "anti-BR1 antibody test." After Ms. Huang's anti-BR1 serum test, her test results showed positive and confirmed the rheumatoid arthritis diagnosis. Ms. Huang was treated with new anti-rheumatoid drugs, including disease-modifying anti-rheumatic drugs (DMARD) and biological disease-modifying anti-rheumatic drugs (bDMARD); her joint swelling disappeared quickly, and she recovered a normal life. Currently, she maintains her treatment, and this research achievement won the honor of the 2022 Future Technology Award in Taiwan. Precisely guided by "anti-BR1 antibody test," China Medical University Hospital (CMUH) found a method to increase 60% rheumatoid arthritis serum anti body positive rate to 80% Dr. Gregory J. Tsay and his R&D team identified a critical section of peptides (BR1) by exploring the correlation between periodontal disease and rheumatoid arthritis to be applied to the diagnosis of rheumatoid arthritis. Through the ELISA approach, the plasma BR1 autoimmune antibody can be applied to help confirm a rheumatoid arthritis diagnosis. The team identified 76 (54.3%) rheumatoid arthritis patients with positive BR1 antibody among 140 patients with rheumatoid arthritis. One-half of the patients with negative RF and ACPA were found to have positive anti-BR1, improving the positive rate of those two traditional tests from 66.3% to 87.1%. The accuracy of the BR1 antibody test kit may elevate the sensitivity of clinical diagnosis for rheumatoid arthritis. Dr. Gregory J. Tsay further explained that the kit is expected to be the third regular test for rheumatoid arthritis diagnosis to achieve the goal of early diagnosis for subsequent early treatment; then patients can get relief from pain and improve their quality of life. SOURCE China Medical University Hospital

Clinical ResultAACR

100 Deals associated with Sulfur Hexafluoride Lipid-Type A Microspheres

External Link

KEGG	Wiki	ATC	Drug Bank
-	Sulfur Hexafluoride Lipid-Type A Microspheres	V08DA05	DB11104

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Vesico-Ureteral Reflux	United States	Bracco Diagnostics, Inc.	22 Dec 2016
Cerebrovascular Disorders	China	Bracco SpA	18 Nov 2014
Liver Diseases	United States	Bracco Diagnostics, Inc.	10 Oct 2014
Cardiovascular Diseases	Norway	Bracco International BV	26 Mar 2001
Cardiovascular Diseases	Iceland	Bracco International BV	26 Mar 2001
Cardiovascular Diseases	Liechtenstein	Bracco International BV	26 Mar 2001
Cardiovascular Diseases	European Union	Bracco International BV	26 Mar 2001
Contrast agents	Iceland	Bracco International BV	26 Mar 2001
Contrast agents	Liechtenstein	Bracco International BV	26 Mar 2001
Contrast agents	European Union	Bracco International BV	26 Mar 2001
Contrast agents	Norway	Bracco International BV	26 Mar 2001

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypoxia-Ischemia, Brain	Phase 3	United States	Bracco Diagnostics, Inc.	01 Dec 2020
Heart Diseases	Phase 3	United States	Bracco Diagnostics, Inc.	01 Oct 2015
Colitis, Ischemic	Phase 2	United States	Bracco Diagnostics, Inc.	04 Nov 2020
Enterocolitis, Necrotizing	Phase 2	United States	Bracco Diagnostics, Inc.	04 Nov 2020
Coronary Artery Disease	Discovery	Germany	Bracco Diagnostics, Inc.	24 Sep 2015
Coronary Artery Disease	Discovery	Italy	Bracco Diagnostics, Inc.	24 Sep 2015
Coronary Artery Disease	Discovery	United States	Bracco Diagnostics, Inc.	24 Sep 2015
Coronary Artery Disease	Discovery	Canada	Bracco Diagnostics, Inc.	24 Sep 2015
Liver Cancer	Discovery	United States	Bracco Diagnostics, Inc.	01 Sep 2009
Visible Lesion	Discovery	United States	Bracco Diagnostics, Inc.	01 Sep 2009

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03821376 (CTgov)	Phase 4	Kidney Neoplasms	12	Lumason	rrburepmgy(jbpbtjbshp) = hgowikymza mcyfptlzko (vpsveyrysu, chaelvotkj - elrakdnarg) View more	-	10 Oct 2024
NCT03687502 (CTgov)	Phase 2	Appendicitis	37	Sulfur hexafluoride lipid-type A microspheres	zwhbvzgihx(dutgluptcw) = ulxpggrqze iozvawxxnm (nvbxwkkyon, ciglxhqdhm - rlnaktkbia) View more	-	01 Dec 2022
NCT03235180 (CTgov)	Phase 4	Crohn Disease	9	Magnetic Resonance Enterography (MRE)+Sulfur Hexafluoride	lgpsakmcel(sbswyzoztr) = emxxxzijlc xcbrmvpfne (skiipwwyoh, ohrwfmozgk - zbesybgsjd) View more	-	10 Nov 2021
PROSPECTIVE INTRA-INDIVIDUAL COMPARISON (ILCA2020)	Not Applicable	-	-	SULFUR HEXAFLUORIDE (Perfluorobutane (C4F10))	joaynezybz(sxqdqcykuq) = nfidrkvvoj xieqfuntlg (vdbfzljszu ) View more	Positive	11 Sep 2020
ESC2020	Not Applicable	-	100	Perfluoropropane contrast	(tzlpwmbdct) = ihduhqgigv nwgkgbpntk (ywzybfuzju ) View more	-	29 Aug 2020
				Sulphur hexafluoride contrast	(tzlpwmbdct) = pvoaccjuwy nwgkgbpntk (ywzybfuzju ) View more
ERS2019	Not Applicable	Asthma	-	SF6	rkpsxmkddn(ljwmoaqjou) = exjxzqhzhf rebnonvgpi (hecqxqbkpr )	Positive	28 Sep 2019
				SF6	rkpsxmkddn(ljwmoaqjou) = ayczljsrcb rebnonvgpi (hecqxqbkpr )
NCT03040323 (CTgov)	Phase 4	Liver Diseases	83	Lumason 60.7Mg Powder for Injection (Biopsy With Lumason)	ipaidqusgp(zuphraubiw) = myuodrwmfc tngnpgocxd (siyrsypnoj, tzkyshrsol - yemwkycyrt) View more	-	24 Jul 2019
				Placebos (Biopsy With Placebos)	ipaidqusgp(zuphraubiw) = smkryudlag tngnpgocxd (siyrsypnoj, dimnbwijzt - stmzlmgydz) View more
2019 ARVO Annual Meeting (ARVO2019)	Not Applicable	-	88	20% sulfur hexafluoride (SF6) gas	hcvinbtqud(gwbvdroape) = epdhlwqugv ftqvvizmkn (gcgkhvuixt ) View more	Positive	01 Jul 2019
				20% sulfur hexafluoride (SF6) gas (Air)	hcvinbtqud(gwbvdroape) = yphkjsqvyk ftqvvizmkn (gcgkhvuixt ) View more
ARVO2017	Not Applicable	Vitreous Hemorrhage	104	SF6	hovzicdnvo(msfjusxmnu) = wafbdtsytg acezhtcvzu (wjwxcpxudk ) View more	Negative	07 May 2017
				Air	hovzicdnvo(msfjusxmnu) = tjpkxqnsgy acezhtcvzu (wjwxcpxudk ) View more
ARVO2016	Not Applicable	Corneal Endothelial Cell Loss	-	Air	(zwvjyyalqi) = mcnubpwwdy tmbkyzuuvn (udbhdxofae ) View more	-	01 May 2016
				SF6	(zwvjyyalqi) = ljebysnpie tmbkyzuuvn (udbhdxofae ) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis